Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
  • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/10—Antioedematous agents; Diuretics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
  • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
  • C07D307/80—Radicals substituted by oxygen atoms

Definitions

• the present invention relates to novel fused cyclic compounds having a GPR40 receptor function modulating action.
• GPR40 receptor agonists useful as agents for the prophylaxis or treatment of diabetes and the like, the following compounds have been reported.
• the present invention aims at providing novel fused cyclic compounds having a GPR40 receptor function modulating action, which are useful as insulin secretagogues or agents for the prophylaxis or treatment of diabetes and the like.
• the present inventors have intensively conducted various studies and found that the compounds represented by the following formula (I) unexpectedly have a superior GPR40 receptor agonist activity, show superior properties as pharmaceutical products such as stability and the like, particularly have low toxicity, and show good pharmacokinetics such as blood sustainability and the like, based on the specific chemical structure thereof, and therefore, can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals, which resulted in the completion of the present invention.
• formula (I) unexpectedly have a superior GPR40 receptor agonist activity, show superior properties as pharmaceutical products such as stability and the like, particularly have low toxicity, and show good pharmacokinetics such as blood sustainability and the like, based on the specific chemical structure thereof, and therefore, can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals, which resulted in the completion of the present invention.
• the present invention relates to
• the compounds of the present invention have a superior GPR40 receptor agonist activity, show superior properties as pharmaceutical products such as stability and the like, particularly have low toxicity and show good kinetics such as blood sustainability and the like, and therefore, can be safe and useful for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.
• halogen atom in the present specification, a fluorine atom, a chlorine atom, a bromine atom and an iodine atom can be mentioned.
• an “optionally substituted hydrocarbon group” in the present specification for example, an “optionally substituted C 1-6 alkyl group”, an “optionally substituted C 2-6 alkenyl group”, an “optionally substituted C 2-6 alkynyl group”, an “optionally substituted C 3-8 cycloalkyl group”, an “optionally substituted C 6-14 aryl group”, an “optionally substituted C 7-16 aralkyl group” and the like can be mentioned.
• C 1-6 alkyl group for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl and the like can be mentioned.
• C 2-6 alkenyl group for example, vinyl, propenyl, isopropenyl, 2-buten-1-yl, 4-penten-1-yl, 5-hexen-1-yl and the like can be mentioned.
• C 2-6 alkynyl group for example, 2-butyn-1-yl, 4-pentyn-1-yl, 5-hexyn-1-yl and the like can be mentioned.
• C 3-8 cycloalkyl group for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like can be mentioned.
• C 6-14 aryl group for example, phenyl, 1-naphthyl, 2-naphthyl, 2-biphenylyl, 3-biphenylyl, 4-biphenylyl, 2-anthryl and the like can be mentioned.
• the C 6-14 aryl may be saturated partially, and as the partially saturated C 6-14 aryl, for example, tetrahydronaphthyl and the like can be mentioned.
• C 7-16 aralkyl group for example, benzyl, phenethyl, diphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 2,2-diphenylethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 2-biphenylylmethyl, 3-biphenylylmethyl, 4-biphenylylmethyl and the like can be mentioned.
• hydroxy group for example, a “hydroxy group”, an “optionally substituted C 1-6 alkoxy group”, an “optionally substituted heterocyclyloxy group”, an “optionally substituted C 6-14 aryloxy group”, an “optionally substituted C 7-16 aralkyloxy group” and the like can be mentioned.
• C 1-6 alkoxy group for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy and the like can be mentioned.
• C 1-6 alkoxy-C 1-6 alkoxy group for example, methoxymethoxy, methoxyethoxy, ethoxymethoxy, ethoxyethoxy and the like can be mentioned.
• heterocyclyloxy group in the present specification, a hydroxy group substituted by a “heterocyclic group” below can be mentioned.
• heterocyclyloxy group tetrahydropyranyloxy, thiazolyloxy, pyridyloxy, pyrazolyloxy, oxazolyloxy, thienyloxy, furyloxy and the like can be mentioned.
• C 1-4 aryloxy group for example, phenoxy, 1-naphthyloxy, 2-naphthyloxy and the like can be mentioned.
• C 7-16 aralkyloxy group for example, benzyloxy, phenethyloxy and the like can be mentioned.
• mercapto group for example, a “mercapto group”, an “optionally substituted C 1-6 alkylthio group”, an “optionally substituted heterocyclylthio group”, an “optionally substituted C 6-14 arylthio group”, an “optionally substituted C 7-16 aralkylthio group” and the like can be mentioned.
• C 1-6 alkylthio group for example, methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio and the like can be mentioned.
• heterocyclylthio group in the present specification, a mercapto group substituted by a “heterocyclic group” below can be mentioned.
• heterocyclylthio group tetrahydropyranylthio, thiazolylthio, pyridylthio, pyrazolylthio, oxazolylthio, thienylthio, furylthio and the like can be mentioned.
• C 6-14 arylthio group for example, phenylthio, 1-naphthylthio, 2-naphthylthio and the like can be mentioned.
• C 7-16 aralkylthio group for example, benzylthio, phenethylthio and the like can be mentioned.
• heterocyclic group for example, a 5- to 14-membered (monocyclic, bicyclic or tricyclic) heterocyclic group containing, as a ring-constituting atom besides carbon atoms, one or two kinds of 1 to 4 hetero atoms selected from a nitrogen atom, a sulfur atom and an oxygen atom, preferably (i) a 5- to 14-membered (preferably 5- to 10-membered) aromatic heterocyclic group, (ii) a 5- to 10-membered non-aromatic heterocyclic group and the like can be mentioned. Of these, a 5- or 6-membered aromatic heterocyclic group is preferable.
• aromatic heterocyclic groups such as thienyl (e.g., 2-thienyl, 3-thienyl), furyl (e.g., 2-furyl, 3-furyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), pyrazinyl, pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4-imidazolyl), pyrazolyl (e.g., 1-pyrazolyl,
• C 1-6 alkyl-carbonyl group for example, acetyl, isobutanoyl, isopentanoyl and the like can be mentioned.
• C 1-6 alkoxy-carbonyl group for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl and the like can be mentioned.
• C 3-8 cycloalkyl-carbonyl group for example, cyclopentylcarbonyl, cyclohexylcarbonyl and the like can be mentioned.
• C 6-14 aryl-carbonyl group for example, benzoyl, 1-naphthoyl, 2-naphthoyl and the like can be mentioned.
• C 7-16 aralkyl-carbonyl group for example, phenylacetyl, 2-phenylpropanoyl and the like can be mentioned.
• C 6-14 aryloxy-carbonyl group for example, phenoxycarbonyl, naphthyloxycarbonyl and the like can be mentioned.
• C 7-16 aralkyloxy-carbonyl group for example, benzyloxycarbonyl, phenethyloxycarbonyl and the like can be mentioned.
• nitrogen-containing heterocyclyl-carbonyl group for example, pyrrolidinylcarbonyl, piperidinocarbonyl and the like can be mentioned.
• C 1-6 alkylsulfonyl group for example, methylsulfonyl, ethylsulfonyl and the like can be mentioned.
• C 6-14 arylsulfonyl group for example, phenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl and the like can be mentioned.
• C 1-6 alkylsulfinyl group for example, methylsulfinyl, ethylsulfinyl and the like can be mentioned.
• C 6-14 arylsulfinyl group for example, phenylsulfinyl, 1-naphthylsulfinyl, 2-naphthylsulfinyl and the like can be mentioned.
• carboxyl group for example, a carboxyl group, a C 1-6 alkoxy-carbonyl group, a C 6-14 aryloxy-carbonyl group, a C 7-16 aralkyloxy-carbonyl group and the like can be mentioned.
• C 1-6 alkyl group in the present specification, the above-mentioned “C 1-6 alkyl group” optionally substituted by 1 to 5 above-mentioned “halogen atoms” can be mentioned.
• halogen atoms for example, methyl, ethyl,.propyl, isoptopyl, butyl, tert-butyl, isobutyl, trifluoromethyl and the like can be mentioned.
• C 1-6 alkoxy group in the present specification, the above-mentioned “C 1-6 alkoxy group” optionally substituted by 1 to 5 above-mentioned “halogen atoms” can be mentioned.
• halogen atoms for example, methoxy, ethoxy, isopropoxy, tert-butoxy, trifluoromethoxy and the like can be mentioned.
• C 1-6 alkyl-amino group an amino group mono- or di-substituted by the above-mentioned “C 1-6 alkyl group(s)” can be mentioned.
• methylamino, ethylamino, propylamino, dimethylamino, diethylamino and the like can be mentioned.
• C 6-14 aryl-amino group an amino group mono- or di-substituted by the above-mentioned “C 6-14 aryl group(s)” can be mentioned.
• phenylamino, diphenylamino, 1-naphthylamino, 2-naphthylamino and the like can be mentioned.
• C 7-16 aralkyl-amino group an amino group mono- or di-substituted by the above-mentioned “C 7-16 aralkyl group(s)” can be mentioned.
• benzylamino, phenethylamino and the like can be mentioned.
• N—C 1-6 alkyl-N—C 6-14 aryl-amino group an amino group substituted by the above-mentioned “C 1-6 alkyl group” and the above-mentioned “C 6-14 aryl group” can be mentioned.
• N-methyl-N-phenylamino, N-ethyl-N-phenylamino and the like can be mentioned.
• N—C 1-6 alkyl-N—C 7-16 aralkyl-amino group an amino group substituted by the above-mentioned “C 1-6 alkyl group” and the above-mentioned “C 7-16 aralkyl group” can be mentioned.
• N-methyl-N-benzylamino, N-ethyl-N-benzylamino and the like can be mentioned.
• a carbamoyl group mono- or di-substituted by the above-mentioned “C 1-6 alkyl group(s)” can be mentioned.
• C 1-6 alkyl group(s) a carbamoyl group mono- or di-substituted by the above-mentioned “C 1-6 alkyl group(s)”
• methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl and the like can be mentioned.
• a carbamoyl group mono- or di-substituted by the above-mentioned “C 6-14 aryl group(s)” can be mentioned.
• phenylcarbamoyl, 1-naphthylcarbamoyl, 2-naphthylcarbamoyl and the like can be mentioned.
• a carbamoyl group mono- or di-substituted by the above-mentioned “C 7-16 aralkyl group(s)” can be mentioned.
• benzylcarbamoyl and the like can be mentioned.
• a carbamoyl group mono- or di-substituted by 5- to 7-membered heterocyclic group(s) can be mentioned.
• a heterocyclic group containing, as a ring-constituting atom besides carbon atoms, one or two kinds of 1 to 4 hetero atoms selected from a nitrogen atom, a sulfur atom and an oxygen atom can be mentioned.
• a sulfamoyl group mono- or di-substituted by the above-mentioned “C 1-6 alkyl group(s)” can be used, for example, methylsulfamoyl, ethylsulfamoyl, dimethylsulfamoyl, diethylsulfamoyl and the like can be mentioned.
• a sulfamoyl group mono- or di-substituted by the above-mentioned “C 6-14 aryl group(s)” can be used, for example, phenylsulfamoyl, diphenylsulfamoyl, 1-naphthylsulfamoyl, 2-naphthylsulfamoyl and the like can be mentioned.
• a sulfamoyl group mono- or di-substituted by the above-mentioned “C 7-16 aralkyl group(s)” can be used, for example, benzylsulfamoyl and the like can be mentioned.
• acyl group groups represented by the formula: —COR 7 , —CO—OR 7 , —SO 2 R 7 , —SOR 7 , —PO(OR 7 ) (OR 8 ), —CO—NR 7a R 8a and —CS—NR 7a R 8a , wherein R 7 and R 8 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R 7a and R 8a are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R 7a and R 8a may form an optionally substituted nitrogen-containing heterocycle together with the adjacent nitrogen atom, and the like can be mentioned.
• nitrogen-containing heterocycle of the “optionally substituted nitrogen-containing heterocycle” which R 7a and R 8a form together with the adjacent nitrogen atom
• a 5- to 7-membered nitrogen-containing heterocycle containing, as a ring-constituting atom besides carbon atoms, at least one nitrogen atom and optionally further containing 1 to 2 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom
• pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, morpholine, thiomorpholine, thiazolidine, oxazolidine and the like can be mentioned.
• the nitrogen-containing heterocycle optionally has 1 to 2 substituents at substitutable positions.
• substituents a hydroxy group, an optionally halogenated C 1-6 alkyl group, a C 6-14 aryl group, a C 7-16 aralkyl group and the like can be mentioned.
• R 1 is R 6 —SO 2 — (wherein R 6 is a substituent) or an optionally substituted 1,1-dioxidotetrahydrothiopyranyl group.
• R 6 an “optionally substituted hydrocarbon group”, an “optionally substituted heterocyclic group”, an “optionally substituted hydroxy group”, an “optionally substituted amino group”, an “optionally substituted mercapto group”, a “cyano group”, an “optionally substituted acyl group”, a “halogen atom” and the like can be mentioned.
• R 6 is preferably an optionally substituted hydrocarbon group, more preferably a C 1-6 alkyl group (preferably methyl, ethyl).
• the “1,1-dioxidotetrahydrothiopyranyl group” of the “optionally substituted 1,1-dioxidotetrahydrothiopyranyl group” for R 1 optionally has 1 to 5 substituents, preferably 1 to 3, substituents at substitutable positions.
• substituents those exemplified as the substituents of the aforementioned “optionally substituted C 3-8 cycloalkyl group” can be used.
• respective substituents may be the same or different.
• the “substituent” is preferably a hydroxy group and the like.
• R 1 is preferably a C 1-6 alkylsulfonyl group (preferably methylsulfonyl, ethylsulfonyl) or a 1,1-dioxidotetrahydrothiopyranyl group, each of which is optionally substituted by 1 to 3 substituents selected from a hydroxy group and the like, more preferably a C 1-6 alkylsulfonyl group (preferably methylsulfonyl, ethylsulfonyl), or a 1,1-dioxidotetrahydrothiopyranyl group optionally substituted by hydroxy group(s).
• R 1 is preferably R 6 —SO 2 — (wherein R 6 is a substituent), more preferably a C 1-6 alkylsulfonyl group (preferably methylsulfonyl, ethylsulfonyl).
• X is a bond or a divalent hydrocarbon group.
• divalent hydrocarbon group for example, a divalent chain hydrocarbon group, a divalent cyclic hydrocarbon group, a divalent chain-cyclic hydrocarbon group can be mentioned. Specifically,
• X is preferably a bond or a C 1-10 alkylene group (preferably a C 1-6 alkylene group, more preferably a straight chain C 1-3 alkylene group), more preferably a C 1-6 alkylene group (preferably a straight chain C 1-3 alkylene group, more preferably —(CH 2 ) 3 —).
• R 2 and R 3 are the same or different and each is a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group or an optionally substituted hydroxy group.
• R 2 and R 3 are the same or different and each is
• R 4 and R 5 are the same or different and each is a C 1-6 alkyl group optionally substituted by hydroxy group(s).
• R 4 and R 5 are the same or different and each is a C 1-6 alkyl group, and more preferably, R 4 and R 5 are each methyl.
• Ring A is a benzene ring optionally further having substituent(s) selected from a halogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxy group and an optionally substituted amino group.
• Ring A is preferably a benzene ring optionally further having 1 to 3 substituents selected from
• Ring B is a 5- to 7-membered ring.
• 5- to 7-membered aromatic rings such as a benzene ring, a 5- to 7-membered aromatic heterocycle and the like
• 5- to 7-membered non-aromatic rings such as a 5- to 7-membered alicyclic hydrocarbon, a 5- to 7-membered non-aromatic heterocycle and the like
• the 5- to 7-membered aromatic heterocycle for example, a 5- to 7-membered monocyclic aromatic heterocycle containing, as a ring-constituting atom besides carbon atoms, 1 to 4 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom can be mentioned.
• furan, thiophene, pyridine, pyrimidine, pyridazine, pyrazine, pyrrole, imidazole, pyrazole, isoxazole, isothiazole, oxazole, thiazole, oxadiazole, thiadiazole, triazole, tetrazole, triazine and the like can be mentioned.
• a saturated or unsaturated alicyclic hydrocarbon having 5 to 7 carbon atoms for example, a C 5-7 cycloalkane, a C 5-7 cycloalkene and the like can be mentioned.
• the 5- to 7-membered non-aromatic heterocycle for example, a 5- to 7-membered monocyclic non-aromatic heterocycle containing, as a ring-constituting atom besides carbon atoms, 1 to 4 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom can be mentioned.
• dihydrofuran, tetrahydrofuran, dihydrothiophene, tetrahydrothiophene, pyrrolidine, pyrroline, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, thiomorpholine, hexamethylenimine, oxazolidine, oxazoline, thiazolidine, thiazoline, imidazolidine, imidazoline, azepane, oxazepane, tetrahydropyridine, dihydropyridine and the like can be mentioned.
• Ring B is preferably a 5- to 7-membered monocyclic non-aromatic heterocycle, more preferably tetrahydrofuran. That is, a ring represented by
• Y is a bond or CH 2 .
• Y is preferably CH 2 .
• R is an optionally substituted hydroxy group.
• the “substituent” which the “optionally substituted hydroxy group” optionally has is preferably a C 1-6 alkyl group.
• R is preferably
• compound (I) having a partial structure of ((3S)-2,3-dihydro-1-benzofuran-3-yl)acetic acid has an excellent GPR40 receptor agonist activity, and is preferable.
• compound (I) As preferable examples of compound (I), the following compounds can be mentioned.
• salts of compound (I) for example, metal salts, an ammonium salt, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids and the like can be mentioned.
• the metal salt include alkali metal salts such as sodium salt, potassium salt and the like; alkaline earth metal salts such as calcium salt, magnesium salt, barium salt and the like; aluminum salt and the like.
• the salt with organic base include a salt with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N′-dibenzylethylenediamine and the like.
• the salt with inorganic acid include a salt with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
• the salt with organic acid include a salt with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like.
• Preferable examples of the salt with basic amino acid include a salt with arginine, lysine, ornithine and the like.
• Preferable examples of the salt with acidic amino acid include a salt with aspartic acid, glutamic acid and the like.
• a pharmacologically acceptable salt is preferable.
• the prodrug of the compound (I) is a compound which is converted to the compound (I) with a reaction due to an enzyme, gastric acid, etc. under the physiological condition in the living body, that is, a compound which is converted to the compound (I) by enzymatic oxidation, reduction, hydrolysis, etc.; a compound which is converted to the compound (I) by hydrolysis etc. due to gastric acid, and the like.
• Examples of a prodrug of compound (I) include a compound wherein an amino group of compound (I) is acylated, alkylated or phosphorylated (e.g., a compound wherein an amino group of compound (I) is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated or tert-butylated); a compound wherein a hydroxy group of compound (I) is acylated, alkylated, phosphorylated or borated (e.g., a compound wherein a hydroxy group of compound (I) is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alany
• a compound wherein a carboxyl group of compound (I) is esterified by C 1-6 alkyl group such as methyl, ethyl, tert-butyl and the like is preferable.
• These compounds can be produced from compound (I) according to a method known per se.
• a prodrug of the compound (I) may be a compound that converts to the compound (I) under physiological conditions as described in Development of Pharmaceutical Products, vol. 7, Molecule Design, 163-198, Hirokawa Shoten (1990).
• the compound obtained in each step can also be used as a crude product in the form of a reaction mixture in the next. reaction, or can be isolated from the reaction mixture according to a conventional method, and further purified easily by a separation method such as recrystallization, distillation, chromatography and the like.
• Compound (I) (e.g., compounds represented by the formulas. (Ia) and (Ia′) (to be abbreviated as compound (Ia) and compound (Ia′) respectively)) can be produced, for example, according to the method shown in the following Scheme 1 or a method analogous thereto.
• R 11 is R 6 —S— (wherein R 6 is as defined above) or a tetrahydrothiopyranyl group
• R′ is an optionally substituted alkoxy group
• L is a leaving group or a hydroxy group
• the other symbols are as defined above.
• compound (V) and compound (VII) are reacted in the presence of an azodicarbonyl compound (e.g., diethyl azodicarboxylate, diisopropyl azodicarboxylate, 1,1′-(azodicarbonyl)dipiperidine) and a phosphine (e.g., triphenylphosphine, tributylphosphine).
• an azodicarbonyl compound e.g., diethyl azodicarboxylate, diisopropyl azodicarboxylate, 1,1′-(azodicarbonyl)dipiperidine
• a phosphine e.g., triphenylphosphine, tributylphosphine
• the amount of compound (VII) to be used is generally about 0.2 to about 5 mol, preferably about 0.5 to about 2 mol, per 1 mol of compound (V).
• the amount of the azodicarbonyl compound and phosphine to be used is generally about 1 to about 5 mol, preferably about 1 to about 2 mol, per 1 mol of compound (V), respectively.
• the reaction is advantageously carried out using a solvent inert to the reaction.
• the solvent is not particularly limited as long as the reaction proceeds, for example, ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoramide and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; nitriles such as acetonitrile, propionitrile and the like; ketones such as acetone, ethyl
• the reaction temperature is generally ⁇ 20 to 200° C., preferably 0 to 100° C.
• the reaction time is generally 5 min to 100 hr, preferably 30 min to 72 hr.
• a halogen atom for example, a halogen atom, an optionally halogenated C 1-6 alkylsulfonyloxy group (e.g., methanesulfonyloxy, ethanesulfonyloxy, trichloromethanesulfonyloxy, trifluoromethanesulfonyloxy), a C 6-10 arylsulfonyloxy group optionally having substituent(s) [for example, a C 6-10 arylsulfonyloxy group (e.g., phenylsulfonyloxy, naphthylsulfonyloxy) optionally having 1 to 3 substituents selected from a C 1-6 alkyl group, a C 1-6 alkoxy group and a nitro group and the like; specifically, phenylsulfonyloxy, m-nitrophenylsulfonyloxy, p-toluenesulfony
• alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; alkaline earth metal hydroxides such as barium hydroxide and the like; alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate and the like; alkali metal hydrogencarbonates such as sodium hydrogencarbonate and the like; alkali metal phosphates such as tripotassium phosphate and the like; acetates such as sodium acetate, ammonium acetate and the like; aromatic amines such as pyridine, lutidine and the like; tertiary amines such as triethylamine, tripropylamine, tributylamine, N-ethyldiisopropylamine, cyclohexyldimethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylpyrrolidine, N-methylmorpholine and the like
• the amount of compound (VII) to be used is generally about 0.2 to about 10 mol, preferably about 0.5 to about 2 mol, per 1 mol of compound (V).
• the amount of the base to be used is generally about 1 to about 10 mol, preferably about 1 to about 3 mol, per 1 mol of compound (V).
• the reaction is advantageously carried out using a solvent inert to the reaction.
• a solvent inert those exemplified in Step 1A-(i) can be mentioned.
• the reaction temperature is generally ⁇ 70 to 150° C., preferably ⁇ 20 to 100° C.
• the reaction time is generally 10 min to 100 hr, preferably 20 min to 72 hr.
• a compound represented by the formula (IV′) (to be abbreviated as compound (IV′)) can be produced by reacting a compound represented by the formula (VI) (to be abbreviated as compound (VI)) with compound (VII) according to the method shown in Step 1A or a method analogous thereto.
• Compound (Ia) can be produced by subjecting compound (Ia′) to a hydrolysis reaction.
• the hydrolysis reaction is carried out using an acid or a base according to a conventional method.
• the acid for example, mineral acids such as hydrochloric acid, sulfuric acid and the like; Lewis acids such as boron trichloride, boron tribromide and the like; organic acids such as trifluoroacetic acid, p-toluenesulfonic acid and the like, and the like can be mentioned.
• Lewis acid can be used concurrently with a thiol or a sulfide.
• alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like
• alkaline earth metal hydroxides such as barium hydroxide and the like
• alkali metal carbonates such as sodium carbonate, potassium carbonate and the like
• alkali metal alkoxides having 1 to 6 carbon atoms such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like
• organic bases including hydrates
• the amount of the acid or base to be used is generally about 0.5 to about 10 mol, preferably about 0.5 to about 6 mol, per 1 mol of compound (Ia′).
• the hydrolysis reaction is carried out without solvent, or using a solvent inert to the reaction.
• the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, propanol and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; organic acids such as formic acid, acetic acid and the like; ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; nitriles such as acetonitrile, propionitrile and the like; ketones such as acetone
• the reaction temperature is generally ⁇ 10 to 200° C., preferably 0 to 120° C.
• the reaction time is generally 10 min to 100 hr, preferably 10 min to 24 hr.
• Compound (IV) can be produced by subjecting compound (IV′) to a hydrolysis reaction.
• the hydrolysis reaction is carried out according to the method shown in Step 2A or a method analogous thereto.
• Compound (Ia) can be produced by subjecting compound (IV) to an oxidation reaction.
• the oxidation reaction is generally carried out using an oxidant according to a conventional method.
• an oxidant for example, hydrogen peroxide, peracetic acid, m-chloroperbenzoic acid, tert-butylhydroperoxide, potassium peroxysulfate, sodium metaperiodate, sodium perborate, sodium hypochlorite, nitric acid, chromic acid, sodium dichromate, potassium permanganate, osmium(VII) oxide, ruthenium (VII) oxide, iodobenzene dichloride, iodobenzene diacetate, halogen, ozone, singlet oxygen and the like can be mentioned.
• the amount of the oxidant to be used is appropriately determined according to the kind of the oxidant. It is generally about 0.25 to about 10 mol, preferably about 0.5 to about 5 mol, per 1 mol of compound (IV).
• the reaction is advantageously carried out using a solvent inert to the reaction.
• a solvent inert those exemplified in Step 2A can be mentioned.
• the reaction temperature is generally ⁇ 10 to 200° C., preferably 0 to 120° C.
• the reaction time is generally 10 min to 100 hr, preferably 10 min to 24 hr.
• Compound (Ia′) can be produced by subjecting compound (IV′) to an oxidation reaction.
• the oxidation reaction is carried out according to the method shown in Step 3A or a method analogous thereto.
• Compound (VII) used in the above-mentioned Scheme 1 can be produced, for example, according to the methods described in Journal of Medicinal Chemistry, vol. 39, pages 4928-4934, 1996; Bioorganic and Medicinal Chemistry, vol. 9, pages 1325-1335, 2001; Heterocycles, vol. 41, pages 647-650, 1995; Journal of Medicinal Chemistry, vol. 43, pages 2049-2063, 2000; Journal of Chemical Society Perkin Transactions 1, pages 2895-2900, 1996 and the like or a method analogous thereto.
• R′′ is a hydrogen atom or an optionally substituted C 1-6 alkoxy group
• L′ is a leaving group
• a compound represented by the formula (IX) (to be abbreviated as compound (IX)) can be produced by reacting a compound represented by the formula (VIII) (to be abbreviated as compound (VIII)) with a compound represented by the formula: R 1 ′—X-L′′ (to be abbreviated as compound R 1 ′—X-L′′) or 1-oxa-6-thiaspiro[2.5]octane according to the method shown in the Step 1A or a method analogous thereto.
• L′′ is a leaving group or a hydroxy group, and the other symbol is as defined above.
• the “leaving group” for L′′ those exemplified as the aforementioned L can be mentioned.
• a compound represented by the formula (X) (to be abbreviated as compound (X)) can be produced by reacting a compound represented by the formula (XI) (to be abbreviated as compound (XI)) with compound R 1 ′—X-L′′ or 1-oxa-6-thiaspiro[2.5]octane according to the method shown in the Step 1A or a method analogous thereto.
• a compound represented by the formula (XII) (to be abbreviated as compound (XII)) can be produced by reacting compound (XI) with a compound represented by the formula: R 1 —X-L′′ (to be abbreviated as compound R 1 —X-L′′) or 1-oxa-6-thiaspiro[2.5]octane 6,6-dioxide according to the method shown in the Step 1A or a method analogous thereto.
• Compound (V) can be produced by reacting a compound represented by the formula (XIII) (to be abbreviated as compound (XIII)) with compound R 1 —X-L′′ or 1-oxa-6-thiaspiro[2.5]octane 6,6-dioxide according to the method shown in the Step 1A or a method analogous thereto.
• XIII formula (XIII)
• Compound (VI) can be produced by reacting compound (XIII) with compound R 1 ′—X-L′′ or 1-oxa-6-thiaspiro[2.5]octane according to the method shown in the Step 1A or a method analogous thereto.
• Compound (X) can be produced by subjecting compound (IX) and a compound represented by the formula: Ar-M (to be abbreviated as compound Ar-M) to a coupling reaction; or, by converting L′ of compound (IX) to a metal (e.g., potassium, sodium, lithium, magnesium, copper, zinc, tin, thallium and the like, they may be complexed) according a method known per se, and subjecting the resulting compound and a compound represented by the formula: Ar-L′′′ (to be abbreviated as compound Ar-L′′′) to a coupling reaction.
• a metal e.g., potassium, sodium, lithium, magnesium, copper, zinc, tin, thallium and the like
• L′′′ is a leaving group
• other symbols are as defined above.
• the “leaving group” for L′′′ those exemplified as the aforementioned L can be mentioned.
• the coupling reaction is generally carried out in the presence of a base.
• a base for example, alkali metal hydrides such as sodium hydride, potassium hydride and the like; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and the like; alkaline earth metal hydroxides such as magnesium hydroxide, calcium hydroxide, barium hydroxide and the like; alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate and the like; alkali metal hydrogencarbonates such as sodium hydrogencarbonate, potassium hydrogencarbonate and the like; alkali metal phosphates such as tripotassium phosphate and the like; alkali metal alkoxides having 1 to 6 carbon atoms such as sodium methoxide, sodium ethoxide, sodium tert-butoxide and the like; organic bases such as trimethylamine, triethylamine, diisopropylethylamine, pyridine, picoline, N-methylpyrrolidine
• the amount of the compound Ar-M or compound Ar-L′′′ to be used is generally about 0.1 to about 10 mol, preferably about 0.5 to about 2 mol, per 1 mol of compound (IX).
• the amount of the base to be used is generally about 1 to about 20 mol, preferably about 1 to about 5 mol, per 1 mol of compound (IX).
• the coupling reaction is advantageously carried out using a solvent inert to the reaction.
• the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, propanol, isopropanol, butanol, tert-butanol and the like; ethers such as 1,4-dioxane, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, diisopropyl ether, 1,2-dimethoxyethane and the like; esters such as ethyl formate, ethyl acetate, n-butyl acetate and the like; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, trichloroethylene and the like; hydrocarbons such as n-hexane, benzene, toluene and the like; amides such as N,N-dimethyl
• the coupling reaction can be promoted by a metal catalyst to be used where necessary.
• metal catalyst metal complexes having various ligands can be used and, for example, palladium compounds [e.g., palladium(II) acetate, tetrakis (triphenylphosphine)palladium(0), bis(triphenylphosphine)palladium(II) chloride, dichlorobis(triethylphosphine)palladium(II), tris(dibenzylideneacetone)dipalladium-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, a complex of palladium(II) acetate and 1,1′-bis(diphenylphosphino)ferrocene]; nickel compounds [e.g., tetrakis(triphenylphosphine)nickel(0), bis(triethylphosphine)nickel(II) chlor
• the amount of the metal catalyst to be used is generally about 0.000001 to about 5 mol, preferably about 0.0001 to about 0.2 mol, per 1 mol of compound (IX).
• the reaction is preferably carried out in an inactive gas (e.g., argon gas or nitrogen gas) stream.
• the reaction temperature is generally ⁇ 10 to 250° C., preferably 0 to 150° C. While the reaction time varies depending on the kinds of compound (IX), compound Ar-M or compound Ar-L′′′, metal catalyst, base and solvent, reaction temperature and the like, it is generally 1 min to 200 hr, preferably 5 min to about 100 hr.
• Compound (XI) can be produced by subjecting compound (VIII) and compound Ar-M to a coupling reaction.
• the coupling reaction can be carried out according to the method shown in the Step 5A or a method analogous thereto.
• Compound (XII) can be produced by subjecting compound (X) to an oxidation reaction.
• the oxidation reaction can be carried out according to the method shown in the Step 3A or a method analogous thereto.
• Compound (V) can be produced from compound (XII).
• Compound (V) wherein L is a hydroxy group [hereinafter sometimes to be abbreviated as compound (V′)] can be produced by subjecting compound (XII) to a reduction reaction.
• the reduction reaction is generally carried out using a reducing agent according to a conventional method.
• a reducing agent for example, metal hydrides such as aluminum hydride, diisobutylaluminum hydride, tributyltin hydride and the like; metal hydride complexes such as sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, lithium aluminum hydride and the like; borane complexes such as borane tetrahydrofuran complex, borane dimethylsulfide complex and the like; alkyl boranes such as thexylborane, disiamylborane and the like; diborane; metals such as zinc, aluminum, tin, iron and the like; alkali metals such as sodium, lithium and the like/liquid ammonia (Birch reduction) and the like can be mentioned.
• the amount of the reducing agent to be used is appropriately determined according to the kind of the reducing agent.
• the amount of the metal hydride, metal hydride complex, borane complex, alkyl borane or diborane to be used is generally about 0.25 to about 10 mol, preferably about 0.5 to about 5 mol, per 1 mol of compound (XII), and the amount of the metal (including alkali metal used for Birch reduction) to be used is generally about 1 to about 20 mol, preferably about 1 to about 5 mol, per 1 mol of compound (XII).
• the reduction reaction is advantageously carried out using a solvent inert to the reaction.
• the solvent is not particularly limited as long as the reaction proceeds, for example, alcohols such as methanol, ethanol, 1-propanol, 2-propanol, tert-butanol and the like; ethers such as diethyl ether, diisopropyl ether, diphenyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; aromatic hydrocarbons such as benzene, toluene and the like; saturated hydrocarbons such as cyclohexane, hexane and the like; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, hexamethylphosphoramide and the like; organic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, methanesulfonic acid and the like; a mixed
• the reaction temperature is generally ⁇ 20 to 100° C., preferably 0 to 80° C. While the reaction time varies depending on the reagent or solvent to be used, it is generally 10 min to 100 hr, preferably 30 min to 50 hr.
• Compound (V) wherein L is a leaving group can be produced by reacting compound (V′) with a halogenating agent or a sulfonylating agent.
• halogenating agent for example, thionyl chloride, phosphorus tribromide and the like can be used.
• compound (V) wherein L is a halogen atom e.g., chlorine, bromine
• a halogen atom e.g., chlorine, bromine
• the reaction of compound (V′) with a halogenating agent is carried out without solvent, or using a solvent inert to the reaction.
• a solvent inert to the reaction for example, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like; ethers such as diethyl ether, diisopropyl ether, tert-butyl methyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; esters such as methyl acetate, ethyl acetate, n-butyl acetate, tert-butyl acetate and the like, and the like can be mentioned.
• the halogenating agent may be used in an excess amount to replace a solvent.
• the amount of the halogenating agent to be used is generally about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (V′).
• the reaction temperature is generally ⁇ 20 to 100° C., preferably 0 to 80° C.
• the reaction time is generally 10 min to 100 hr, preferably 30 min to 48 hr.
• sulfonylating agent for example, sulfonyl halides such as methanesulfonyl chloride, benzenesulfonyl chloride, p-toluenesulfonyl chloride and the like; sulfonic acid anhydrides such as methanesulfonic anhydride, trifluoromethanesulfonic anhydride and the like, and the like can be used.
• compound (V) wherein L is, for example, methanesulfonyloxy, benzenesulfonyloxy, p-toluenesulfonyloxy, trifluoromethanesulfonyloxy and the like, can be produced.
• reaction of compound (V′) with a sulfonylating agent is generally carried out in a solvent inert to the reaction, in the presence of a base.
• solvent inert to the reaction those exemplified in the above-mentioned reaction of compound (V′) with the halogenating agent can be mentioned.
• the amount of the sulfonylating agent to be used is generally about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (V′).
• amines such as triethylamine, N-methylmorpholine and the like
• alkali metal hydrogencarbonates such as sodium hydrogencarbonate, potassium hydrogencarbonate and the like
• alkali metal carbonates such as potassium carbonate and the like, and the like
• the amount of the base to be used is generally about 1 to about 10 mol, preferably about 1 to about 5 mol, per 1 mol of compound (V′).
• the reaction temperature is generally ⁇ 20 to 100° C., preferably ⁇ 10 to 80° C.
• the reaction time is generally 10 min to 24 hr, preferably 30 min to 8 hr.
• Compound (XIII) can be produced from compound (XI) according to the method shown in the Step 7A or a method analogous thereto.
• Compound (VI) can be produced from compound (X) according to the method shown in the Step 7A or a method analogous thereto.
• an optically active form of (6-hydroxy-2,3-dihydro-1-benzofuran-3-yl)acetic acid (which is a particularly useful compound) or a salt thereof or compound (III) including the compound can be produced, for example, according to the method shown in the following Scheme 3 or a method analogous thereto.
• An optically active form of compound (III) can be produced by subjecting compound (II) to an asymmetric reduction reaction.
• the asymmetric reduction reaction is advantageously carried out by hydrogenation using an optically active rhodium-phosphine complex as a catalyst, in the presence of a base.
• the optically active rhodium-phosphine complex can be obtained by producing from an optically active phosphine and a rhodium complex according to a known method, and isolating or purifying according to a known means (e.g., concentration, solvent extraction, fractionation, crystallization, recrystallization, chromatography).
• a known means e.g., concentration, solvent extraction, fractionation, crystallization, recrystallization, chromatography
• the optically active rhodium-phosphine complex can be also prepared by adding an optically active phosphine and a rhodium complex to a reaction system.
• the timing and order of addition of the optically active phosphine and rhodium complex to the reaction system is not particularly limited, and they may be simultaneously added to the reaction system, or added separately in a staggered manner.
• BINAP 2,2′-bis-(diphenylphosphino)-1,1′-binaphthyl
• BINAP derivatives which has substituent(s) (e.g., a C 1-6 alkyl group, a C 6-14 aryl group and the like) on the naphthyl ring of BINAP, for example, 2,2′-bis-(diphenylphosphino)-6,6′-dimethyl-1,1′-binaphthyl
• DIOP DIOP, DuPHOS, BPE, BoPhoz, Josiphos, Walphos, Mandyphos, Taniaphos, FerroTANE and the like are preferable, and FerroTANE and BPE are particularly preferable.
• rhodium complex for example, acetylacetonatobis(cyclooctene)rhodium(I), acetylacetonatobis(ethylene)rhodium(I), acetylacetonatobis(1,5-cyclooctadiene)rhodium(I), bis(1,5-cyclooctadiene)rhodium tetrafluoroborate(I), (1,5-cyclooctadiene)rhodium trifluoromethanesulfonate(I), chlorobis(cyclooctene)rhodium(I)dimer, chlorobis(ethylene)rhodium(I)dimer, chloro(1,5-cyclooctadiene)rhodium(I) dimer, chloro(dicarbonyl)rhodium(I) dimer, chloronorbornanedienerhodium(I) dimer, chlorotris(triphenyl)
• bis(1,5-cyclooctadiene)rhodium tetrafluoroborate(I) and (1,5-cyclooctadiene)rhodium trifluoroinethanesulfonate(I) are preferable, and (1,5-cyclooctadiene)rhodium trifluoromethanesulfonate(I) is particularly preferable.
• the amount of the optically active rhodium-phosphine complex to be used varies depending on the reaction container, reaction manner and the like, for example, it is about 0.1 to about 0.00001 mol, preferably about 0.02 to about 0.0001 mol, per 1 mol of compound (II).
• alkali metal hydroxides such as potassium hydroxide, sodium hydroxide, cesium hydroxide and the like
• alkali metal alkoxides having 1 to 6 carbon atoms such as lithium methoxide, sodium methoxide, potassium methoxide, lithium ethoxide, sodium ethoxide, potassium ethoxide, lithium propoxide, sodium propoxide, potassium propoxide, lithium isopropoxide, sodium isopropoxide, potassium isopropoxide, potassium tert-butoxide and the like
• alkali metal thioalkoxides having 1 to 6 carbon atoms such as sodium thiomethoxide and the like, and the like
• an alkali metal hydroxide and an alkali metal alkoxide are preferable, and an alkali metal alkoxide having 1 to 6 carbon atoms is particularly preferable.
• the amount of the base to be used is about 0.01 to about 100 mol, preferably about 0.1 to about 10 mol, per 1 mol of compound (II).
• This reaction is generally carried out in a solvent.
• the solvent is not particularly limited as long as it is inert to the reaction and can solubilize the starting material compound and the catalyst, for example, aromatic hydrocarbons such as toluene, xylene and the like; aliphatic hydrocarbons such as heptane, hexane and the like; halogenated hydrocarbons such as methylene chloride and the like; ethers such as diethyl ether, tetrahydrofuran and the like; alcohols such as methanol, ethanol, 2-propanol, butanol, benzyl alcohol and the like; nitriles such as acetonitrile and the like; amides such as N,N-dimethylformamide and the like; sulfoxides such as dimethyl sulfoxide and the like, and the like can be used.
• aromatic hydrocarbons such as toluene, xylene and the like
• aliphatic hydrocarbons
• the above-mentioned solvents are preferably used for the reaction after drying and deaeration.
• the amount of the solvent to be used is appropriately determined according to the solubility of compound (II) and the like.
• an alcohol preferably methanol
• the reaction proceeds in a condition ranging from a near solventless system to a system wherein not less than 100-fold weight of the alcohol solvent, relative to compound (II).
• the solvent is preferably used in about 2- to about 50-fold weight relative to compound (II).
• the hydrogenation can be carried out by any of a batch reaction and a continuous reaction.
• the hydrogenation is carried out in the presence of hydrogen, where the hydrogen pressure is, for example, 1 to 200 atm, preferably 1 to 10 atm.
• the reaction temperature is generally ⁇ 30° C. to 100° C., preferably 10° C. to 80° C., more preferably 20° C. to 50° C.
• the reaction time is generally 0.5 to 48 hr, preferably 1 to 24 hr.
• optically active form of compound (III) obtained by the asymmetric reduction reaction can be purified by a known means (e.g., fractional recrystallization, chiral column method).
• amino-protecting group for example, formyl group; C 1-6 alkyl-carbonyl group (e.g., acetyl, propionyl), benzoyl group, C 1-6 alkoxy-carbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl (Boc)), allyloxycarbonyl group (Alloc), phenyloxycarbonyl group, fluorenylmethyloxycarbonyl group (Fmoc), C 7-10 aralkyloxycarbonyl group (e.g., benzyloxycarbonyl), trityl group, phthaloyl group, dithiasuccinoyl group and N,N-dimethylaminomethylene group, each optionally having substituent(s), and the like can be used.
• C 1-6 alkyl-carbonyl group e.g., acetyl, propionyl
• benzoyl group C 1-6
• substituent for example, phenyl group, halogen atom, C 1-6 alkyl-carbonyl group (e.g., acetyl, propionyl, valeryl), optionally halogenated C 1-6 alkoxy group, nitro group and the like are used.
• the number of the substituent(s) is about 1 to 3.
• carboxyl-protecting group for example, C 1-6 alkyl group, allyl group, benzyl group, phenyl group, trityl group and trialkylsilyl group (e.g., trimethylsilyl, tert-butyldimethylsilyl, triisopropylsilyl), each optionally having substituent(s), and the like can be used.
• substituent for example, halogen atom, formyl group, C 1-6 alkyl-carbonyl group (e.g., acetyl, propionyl, valeryl), optionally halogenated C 1-6 alkoxy group, nitro group, C 1-6 alkyl group, C 6-10 aryl group (e.g., phenyl, naphthyl) and the like are used.
• the number of the substituent(s) is about 1 to 3.
• hydroxy-protecting group for example, formyl group; C 1-6 alkyl group, C 7-10 aralkyl group, C 1-6 alkyl-carbonyl group (e.g., acetyl, propionyl), benzoyl group, phenyloxycarbonyl group, C 7-10 aralkyloxy-carbonyl group (e.g., benzyloxycarbonyl), C 7-10 aralkyl-carbonyl group (e.g., benzylcarbonyl), tetrahydropyranyl group, tetrahydrofuranyl group, furanyl group and trialkylsilyl group (e.g., trimethylsilyl, tert-butyldimethylsilyl, triisopropylsilyl), each optionally having substituent(s), and the like can be used.
• formyl group C 1-6 alkyl group, C 7-10 aralkyl group, C 1-6 alkyl-carbonyl group (
• substituent for example, halogen atom, C 1-6 alkyl group, C 7-10 aralkyl group (e.g., benzyl), C 6-10 aryl group (e.g., phenyl, naphthyl), C 1-6 alkoxy group, nitro group and the like are used.
• the number of the substituent(s) is about 1 to 4.
• C 1-6 alkyl group and C 7-20 aralkyl group e.g., benzyl, trityl
• substituent for example, halogen atom, C 1-6 alkyl group, phenyl group, C 7-10 aralkyl group (e.g., benzyl), C 1-6 alkoxy group, nitro group and the like are used.
• the number of the substituent(s) is about 1 to 4.
• a method known per se or a method analogous thereto is used. For example, treatment with acid, base, ultraviolet rays, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate, tetrabutylammonium fluoride, palladium(II) acetate and the like or reduction are used.
• the compound of the present invention can be synthesized by further using hydrolysis, deprotection, acylation, alkylation, hydrogenation, oxidation, reduction, carbon chain extension and substituent exchange reaction alone or in a combination of two or more thereof.
• hydrolysis, deprotection, acylation, alkylation, hydrogenation, oxidation, reduction, carbon chain extension and substituent exchange reaction alone or in a combination of two or more thereof.
• the product When the object product is obtained in a free form by the above-mentioned reactions, the product may be converted to a salt by a conventional method, and when it is obtained as a salt, the product may be converted to a free form or a different salt by a conventional method.
• the compound of the present invention thus obtained can be isolated and purified from a reaction mixture by a known means, such as, phase transfer, concentration, solvent extraction, fractionation, crystallization, recrystallization, chromatography and the like.
• compound (I) When compound (I) is present as a configurational isomer (stereoisomer), diastereomer, conformer or the like, each can be isolated by the above separation and purification methods on demand. In addition, when compound (I) is in the form of racemates, they can be separated into S- and R-forms by any conventional optical resolution.
• compound (I) may be a hydrate or non-hydrate.
• a hydrate of compound (I) normally shows an excellent preservation stability.
• Compound (I) may be labeled with an isotope (e.g., 3 H, 14 C, 35 S and the like) or the like.
• an isotope e.g., 3 H, 14 C, 35 S and the like
• compound (I) and a prodrug thereof have a GPR40 receptor function modulating action, particularly, a GPR40 receptor agonist activity, and are low in toxicity (e.g., influence on hematological parameters such as red blood cell number, hematocrit value, hemoglobin concentration, MCH, MCHC, MCV, platelet count, leukocyte count, blood reticulocyte count, leukocyte classification and the like; blood biochemical parameters such as total protein, albumin, A/G ratio, glucose, total cholesterol, triglyceride, urea nitrogen, creatinine, total bilirubin, AST, ALT, LDH, ALP, CK, Na, K, Cl, calcium, inorganic phosphorus, retinol (vitamin A) and the like) and a fewer side effects (e.g., acute toxicity, chronic toxicity, genetic toxicity, reproductive toxicity, cardiotoxicity, drug interaction, carcino
• a GPR40 receptor function modulating action particularly, a GPR40 receptor
• the compound of the present invention shows a superior GPR40 receptor function modulating action in mammals (e.g., mouse, rat, hamster, rabbit, cat, dog, bovine, sheep, monkey, human), and is useful as modulators of physiological function in which GPR40 receptor is involved or as agents for the prophylaxis or treatment of pathology or disease in which GPR40 receptor is involved.
• mammals e.g., mouse, rat, hamster, rabbit, cat, dog, bovine, sheep, monkey, human
• the compound of the present invention is useful as insulin secretion modulators (preferably insulin secretagogues), hypoglycemic agents and pancreatic ⁇ cell protectors.
• the compound of the present invention is useful as blood glucose level-dependent insulin secretagogues based on the GPR40 receptor agonist activity thereof. That is, different from sulfonylureas, the compound of the present invention is useful as insulin secretagogues that do not cause hypoglycemia.
• the compound of the present invention is useful as agents for the prophylaxis or treatment of diseases such as diabetes, impaired glucose tolerance, ketosis, acidosis, diabetic complications (e.g., diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, macroangiopathy, diabetic gangrene), macular edema, hyperlipidemia, genital disorder, skin disease, arthropathy, osteopenia, arteriosclerosis, thrombotic disease, dyspepsia, memory and learning disorder, depression, depression and mania, schizophrenia, attention deficit hyperactivity disorder, visual disorder, appestat disorder (e.g., hyperorexia), obesity, hypoglycemia, hypertension, edema, insulin resistance, unstable diabetes, fatty atrophy, insulin allergy, insulinoma, lipotoxicity, hyperinsulinemia, cancers (e.g., breast cancer), metabolic syndrome, immune diseases (e.g., immunodeficiency), inflammatory disease (e.g., enteritis, arthritis, allergy),
• diabetes includes type I diabetes, type II diabetes, gestational diabetes and obese diabetes.
• hyperlipidemia includes hypertriglyceridemia, hypercholesterolemia, hypo-high-density-lipoproteinemia, postprandial hyperlipidemia and the like.
• diabetes is a condition showing any of a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 126 mg/dl, a 75 g oral glucose tolerance test (75 g OGTT) 2 h level (glucose concentration of intravenous plasma) of not less than 200 mg/dl, and a non-fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 200 mg/dl.
• a condition not falling under the above-mentioned diabetes and different from “a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of less than 110 mg/dl or a 75 g oral glucose tolerance test (75 g OGTT) 2 h level (glucose concentration of intravenous plasma) of less than 140 mg/dl” (normal type) is called a “borderline type”.
• ADA American Diabetes Association
• WHO reported new diagnostic criteria of diabetes.
• diabetes is a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 126 mg/dl or a 75 g oral glucose tolerance test 2 h level (glucose concentration of intravenous plasma) of not less than 200 mg/dl.
• impaired glucose tolerance is a condition showing a 75 g oral glucose tolerance test 2 h level (glucose concentration of intravenous plasma) of not less than 140 mg/dl and less than 200 mg/dl.
• a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 110 mg/dl and less than 126 mg/dl is called IFG (Impaired Fasting Glucose).
• the IFG (Impaired Fasting Glucose) means a condition showing a fasting blood glucose level (glucose concentration of intravenous plasma) of not less than 110 mg/dl and less than 126 mg/dl, and it is called IFG (Impaired Fasting Glycemia).
• the compound of the present invention can be also used as an agent for the prophylaxis or treatment of diabetes, borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) and IFG (Impaired Fasting Glycemia), as determined according to-the above-mentioned new diagnostic criteria. Moreover, the compound of the present invention can prevent progress of borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) or IFG (Impaired Fasting Glycemia) into diabetes.
• the compound of the present invention is also useful as a therapeutic agent for diabetes with sulfonylurea secondary failure and affords a superior insulin secretion effect and a hypoglycemic effect for diabetic patients for whom sulfonylurea compounds and fast-acting insulin secretagogues fail to provide an insulin secretion effect, and therefore, fail to provide a sufficient hypoglycemic effect.
• a compound having a sulfonylurea skeleton or a derivative thereof e.g., tolbutamide, glibenclamide, gliclazide, chlorpropamide, tolazamide, acetohexamide, glyclopyramide, glimepiride, glipizide, glybuzole and the like
• a compound having a sulfonylurea skeleton or a derivative thereof e.g., tolbutamide, glibenclamide, gliclazide, chlorpropamide, tolazamide, acetohexamide, glyclopyramide, glimepiride, glipizide, glybuzole and the like
• a compound that promotes insulin secretion from pancreatic ⁇ cell in the same manner as a sulfonylurea compound, though it does not have a sulfonylurea skeleton such as glinide compounds (e.g., repaglinide, senaglinide, nateglinide, mitiglinide or a calcium salt hydrate thereof etc.), and the like, can be mentioned.
• glinide compounds e.g., repaglinide, senaglinide, nateglinide, mitiglinide or a calcium salt hydrate thereof etc.
• the compound of the present invention shows low toxicity, and can be safely administered orally or parenterally (e.g., topical, rectal, intravenous administration) in the form of the compound of the present invention as it is or after being admixed with a pharmacologically acceptable carrier to give a pharmaceutical preparation, according to a method known per se employed for general production methods for pharmaceutical preparations.
• the dosage form of the aforementioned pharmaceutical preparation is, for example, an oral agent such as tablets (inclusive of sublingual tablets and orally disintegrable tablets), capsules (inclusive of soft capsules and micro capsules), granules, powders, troches, syrups, emulsions, suspensions and the like; or a parenteral agent such as injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, drip infusions), external agents (e.g., transdermal preparations, ointments), suppositories (e.g., rectal suppositories, vaginal suppositories), pellets, nasal preparations, pulmonary preparations (inhalations), ophthalmic preparations and the like.
• an oral agent such as tablets (inclusive of sublingual tablets and orally disintegrable tablets), capsules (inclusive of soft capsules and micro capsules), granules, powders, troches, syrups, e
• compositions may be controlled-release preparations (e.g., sustained-release microcapsules) such as immediate-release preparations, sustained-release preparations and the like.
• the content of the compound of the present invention in a pharmaceutical preparation is about 0.01 to about 100% by weight relative to the whole preparation.
• the dose varies depending on the administration subject, administration route, diseases, condition and the like, for example, the compound of the present invention (as an active ingredient) can be orally administered to a patient with diabetes (body weight about 60 kg) in about 0.01 to about 30 mg/kg body weight per day, preferably about 0.1 to about 20 mg/kg body weight per day, more preferably about 1 to about 20 mg/kg body weight per day, which may be given at once or in several portions a day.
• various organic or inorganic carrier substances conventionally used as a preparation material can be mentioned.
• excipient, lubricant, binder and disintegrant for solid preparations solvent, dissolution aids, suspending agent, isotonicity agent, buffer and soothing agent for liquid preparations and the like
• conventional additives such as preservatives, antioxidants, coloring agents, sweetening agents, adsorbing agents, wetting agents and the like can be used.
• excipient for example, lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light anhydrous silicic acid and the like can be mentioned.
• lubricant for example, magnesium stearate, calcium stearate, talc, colloidal silica and the like can be mentioned.
• binder for example, crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, saccharose, gelatin, methylcellulose, carboxymethylcellulose sodium and the like can be mentioned.
• disintegrant for example, starch, carboxymethylcellulose, carboxymethylcellulose calcium, carboxymethylstarch sodium, L-hydroxypropylcellulose and the like can be mentioned.
• solvent for example, water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, olive-oil and the like can be mentioned.
• dissolution aids for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like can be mentioned.
• suspending agent for example, surfactants such as stearyltriethanolamine, sodium lauryl sulfate, lauryl aminopropionate, lecithin, benzalkonium chloride, benzethonium chloride, glycerol monostearate and the like; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and the like, and the like can be mentioned.
• surfactants such as stearyltriethanolamine, sodium lauryl sulfate, lauryl aminopropionate, lecithin, benzalkonium chloride, benzethonium chloride, glycerol monostearate and the like
• hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropy
• glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like can be mentioned.
• buffers such as phosphates, acetates, carbonates, citrates and the like, and the like can be mentioned.
• the soothing agent for example, benzyl alcohol and the like can be mentioned.
• preservative for example, p-hydroxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like can be mentioned.
• antioxidant for example, sulfites, ascorbic acid, ⁇ -tocopherol and the like can be mentioned.
• water-soluble edible tar pigments e.g., foodcolors such as Food Color Red Nos. 2 and 3,. Food Color Yellow Nos. 4 and 5, Food Color Blue Nos. 1 and 2 and the like
• water insoluble lake pigments e.g., aluminum salt of the aforementioned water-soluble edible tar pigment and the like
• natural pigments e.g., ⁇ -carotene, chlorophil, red iron oxide etc.
• sweetening agent for example, saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia and the like can be mentioned.
• the compound of the present invention can be used in combination with drugs other than the compound of the present invention.
• drugs that can be used in combination with the compound of the present invention for example, other therapeutic agents for diabetes, therapeutic agents for diabetic complications, therapeutic agents for hyperlipidemia, antihypertensive agents, antiobesity agents, diuretics, chemotherapeutic agents, immunotherapeutic agents, antiinflammatory agents, antithrombotic agents, therapeutic agents for osteoporosis, vitamins, antidementia agents, therapeutic agents for pollakiuria or urinary incontinence, therapeutic agents for dysuria and the like can be mentioned. Specifically, the following agents can be mentioned.
• insulin preparations e.g., animal insulin preparations extracted from pancreas of bovine or swine; human insulin preparations genetically synthesized using Escherichia coli or yeast; zinc insulin; protamine zinc insulin; fragment or derivative of insulin (e.g., INS-1), oral insulin preparation
• PPAR function modulators e.g., pioglitazone or a salt thereof (preferably hydrochloride), rosiglitazone or a salt thereof (preferably maleate), Reglixane, Netoglitazone, FK-614, Rivoglitazone, compounds described in WO01/38325, Tesaglitazar, Ragaglitazar, Muraglitazar, ONO-5816, Edaglitazone, LM-4156, Metaglidasen (MBX-102), Naveglitazar, MX-6054, LY-510929, Balaglitazone, T-131 or a salt thereof, THR-0921
• aldose reductase inhibitors e.g., Tolrestat, Epalrestat, Zenarestat, Zopolrestat, Fidarestat, Minalrestat, ranirestat, CT-112
• neurotrophic factors and increasing drugs thereof e.g., NGF, NT-3, BDNF, neurotrophin production-secretion promoters described in WO01/14372 (e.g., 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole)
• PKC protein kinase C
• ruboxistaurin mesylate AGE inhibitors
• AGE inhibitors e.g., ALT-945, pimagedine, pyratoxanthine, N-phenacylthiazolium bromide (ALT-766), EXO-226, ALT-711, Pyridorin, Pyridoxamine
• HMG-COA reductase inhibitors e.g., pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, pitavastatin, rosuvastatin or a salt thereof (e.g., sodium salt, calcium salt)
• squalene synthase inhibitors e.g., compounds described in WO97/10224, such as N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3, 5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid
• fibrate compounds e.g., bezafibrate, clofibrate, simfibrate, clinofibrate
• antioxidants e.g., lipoic acid
• antihypertensive agents examples include angiotensin converting enzyme inhibitors (e.g., captopril, enalapril, delapril), angiotensin II antagonists (e.g., losartan, candesartan cilexetil, eprosartan, valsartan, telmisartan, irbesartan, olmesartan medoxomil, tasosartan, 1-[[2′-(2,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid), calcium channel blockers (e.g., manidipine, nifedipine, amlodipine, efonidipine, nicardipine), potassium channel openers (e.g., levcromakalim, L-27152,
• antiobesity agents examples include antiobesity agents acting on the central nervous system (e.g., dexfenfluramine, fenfluramine, phentermine, sibutramine, amfepramone, dexamphetamine, mazindol, phenylpropanolamine, clobenzorex; MCH receptor antagonists (e.g., SB-568849; SNAP-7941; compounds described in WO01/82925 and WO01/87834); neuropeptide Y antagonists (e.g., CP-422935); cannabinoid receptor antagonists (e.g., SR-141716, SR-147778); ghrelin antagonists; 11 ⁇ -hydroxysteroid dehydrogenase inhibitors (e.g., BVT-3498)), pancreatic lipase inhibitors (e.g., orlistat, cetilistat (ATL-962)), ⁇ 3 agonists (e.g., AJ
• diuretics examples include xanthine derivatives (e.g., sodium salicylate and theobromine, calcium salicylate and theobromine), thiazide preparations (e.g., ethiazide, cyclopenthiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benzylhydrochlorothiazide, penflutizide, polythiazide, methyclothiazide), antialdosterone preparations (e.g., spironolactone, triamterene), carbonate dehydratase inhibitors (e.g., acetazolamide), chlorobenzenesulfonamide preparations (e.g., chlortalidone, mefruside, indapamide), azosemide, isosorbide, etacrynic acid, piretanide, bumetanide, furosemide and the like.
• chemotherapeutic agents examples include alkylating agents (e.g., cyclophosphamide, ifosfamide), metabolic antagonists (e.g., methotrexate, 5-fluorouracil), antitumor antibiotics (e.g., mitomycin, adriamycin), plant-derived antitumor agents (e.g., vincristine, vindesine, Taxol), cisplatin, carboplatin, etoposide and the like.
• alkylating agents e.g., cyclophosphamide, ifosfamide
• metabolic antagonists e.g., methotrexate, 5-fluorouracil
• antitumor antibiotics e.g., mitomycin, adriamycin
• plant-derived antitumor agents e.g., vincristine, vindesine, Taxol
• cisplatin carboplatin, etoposide and the like.
• immunotherapeutic agents examples include microorganism or bacterial components (e.g., muramyl dipeptide derivatives, Picibanil), polysaccharides having immunity potentiating activity (e.g., lentinan, schizophyllan, krestin), cytokines obtained by genetic engineering techniques (e.g., interferon, interleukin (IL)), colony stimulating factors (e.g., granulocyte colony stimulating factor, erythropoietin) and the like.
• interleukins such as IL-1, IL-2, IL-12 and the like are preferable.
• antiinflammatory agents examples include non-steroidal antiinflammatory agents such as aspirin, acetaminophen, indomethacin and the like.
• antithrombotic agents examples include heparins (e.g., heparin sodium, heparin calcium, dalteparin sodium), warfarins (e.g., warfarin potassium), anti-thrombin drugs (e.g., argatroban), thrombolytic agents (e.g., urokinase, tisokinase,reteplase, nateplase, monteplase, pamiteplase), platelet aggregation inhibitors (e.g., ticlopidine hydrochloride, cilostazol, ethyl icosapentate, beraprost sodium, sarpogrelate hydrochloride) and the like.
• heparins e.g., heparin sodium, heparin calcium, dalteparin sodium
• warfarins e.g., warfarin potassium
• anti-thrombin drugs e.g., argatroban
• Examples of the therapeutic agents for osteoporosis include alfacalcidol, calcitriol, elcatonin, calcitonin salmon, estriol, ipriflavone, pamidronate disodium, alendronate sodium hydrate, reminderonate disodium, risedronate disodium and the like.
• vitamins examples include vitamin B 1 , vitamin B 12 and the like.
• antidementia agents examples include tacrine, donepezil, rivastigmine, galanthamine and the like.
• Examples of the therapeutic agents for pollakiuria or urinary incontinence include flavoxate hydrochloride, oxybutynin hydrochloride, propiverine hydrochloride and the like.
• Examples of the therapeutic agents for dysuria include acetylcholine esterase inhibitors (e.g., distigmine) and the like.
• drugs having a cachexia-improving action established in animal models and clinical situations such as cyclooxygenase inhibitors (e.g., indomethacin), progesterone derivatives (e.g., megestrol acetate), glucosteroids (e.g., dexamethasone), metoclopramide agents, tetrahydrocannabinol agents, fat metabolism improving agents (e.g., eicosapentanoic acid), growth hormones, IGF-1, antibodies to a cachexia-inducing factors such as TNF- ⁇ , LIF, IL-6, oncostatin M and the like, and the like can be used in combination with the compound of the present invention.
• cyclooxygenase inhibitors e.g., indomethacin
• progesterone derivatives e.g., megestrol acetate
• glucosteroids e.g., dexamethasone
• metoclopramide agents
• glycosylation inhibitors e.g., ALT-711
• nerve regeneration promoting drugs e.g., Y-128, VX853, prosaptide
• antidepressants e.g., desipramine, amitriptyline, imipramine
• antiepileptics e.g., lamotrigine, Trileptal, Keppra, Zonegran, Pregabalin, Harkoseride, carbamazepine
• antiarrhythmic agents e.g., mexiletine
• acetylcholine receptor ligands e.g., ABT-594
• endothelin receptor antagonists e.g., ABT-627
• monoamine uptake inhibitors e.g., tramadol
• narcotic analgesics e.g., morphine
• GABA receptor agonists e.g., gabapentin, gabapentin MR agent
• ⁇ 2 receptor agonists e.
• the combination drug is preferably an insulin preparation, a PPAR function modulator (preferably pioglitazone or hydrochloride thereof), an ⁇ -glucosidase inhibitor (preferably voglibose), a biguanide (preferably metformin or hydrochloride thereof), a sulfonylurea (preferably glibenclamide, glimepiride), mitiglinide or calcium salt hydrate thereof, nateglinide, a dipeptidyl peptidase IV inhibitor (preferably alogliptin or benzoate thereof, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile or succinate thereof, 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-
• the administration time of the compound of the present invention and the concomitant drug is not restricted, and the compound of the present invention and the concomitant drug may be administered simultaneously, or may be administered at staggered times, to an administration subject.
• the dosage of the concomitant drug may be determined according to the dose clinically used, and can be appropriately selected depending on an administration subject, administration route, disease, combination and the like.
• the following methods can be mentioned: (1) The compound of the present invention and the concomitant drug are simultaneously formulated to give a single preparation which is administered. (2) The compound of the present invention and the concomitant drug are separately formulated to give two kinds of preparations which are administered simultaneously by the same administration route. (3) The compound of the present invention and the concomitant drug are separately formulated to give two kinds of preparations which are administered by the same administration route at staggered times. (4) The compound of the present invention and the concomitant drug are separately formulated to give two kinds of preparations which are administered simultaneously by the different administration routes.
• the compound of the present invention and the concomitant drug are separately formulated to give two kinds of preparations which are administered by the different administration routes at staggered times (for example, the compound of the present invention and the concomitant drug are administered in this order, or in the reverse order), and the like.
• the present invention also relates to (6-hydroxy-2,3-dihydro-1-benzofuran-3-yl)acetic acid, which is a useful compound as a starting material for producing the compound of the present invention, or a salt thereof.
• the compound can be produced, for example, according to the method described in below-mentioned Example 17.
• the compound may be a racemate or an optically active form.
• a salt of the compound those similar to the salt of compound (I) can be mentioned, with preference given to a metal salt.
• the present invention provides a production method of an optically active form of a compound represented by the formula (III):
• Z is preferably a hydroxy group or a C 1-6 alkoxy group, more preferably a hydroxy group.
• R is preferably a hydroxy group or a C 1-6 alkoxy group, more preferably a hydroxy group.
• salts of compound (II) and compound (III) those similar to the salt of compound (I) can be mentioned, with preference given to a metal salt, respectively.
• room temperature in the following Reference Examples and Examples indicates the range of generally from about 10° C. to about 35° C.
• the chemical yield is an isolation yield (mol/mol %) or was obtained by high performance liquid chromatography.
• the optical purity (asymmetric yield) of optically active forms was evaluated according to enantiomeric excess (% e.e.).
• the solvent used for chromatography is in % by volume and other “%” is in % by weight.
• melting point, mass spectrum (MS) and nuclear magnetic resonance spectrum (NMR) were measured under the following conditions melting point measurement tools: Yanagimoto micromelting point measuring apparatus, or Büchi melting point measuring apparatus type B-545 was used.
• the numerical value in the parentheses in the “retention time” of the conditions of high performance liquid chromatography shows the ratio of each optical isomer produced in a mixture of the optical isomers.
• Tetrahydro-2H-thiopyran-4-ol (0.0591 g, 0.500 mmol), triphenylphosphine (0.157 g, 0.600 mmol) and diethyl azodicarboxylate (40% solution in toluene, 0.272 mL, 0.600 mmol) were added, and the mixture was further stirred for 1.5 hr.
• the reaction mixture was ice-cooled, 2 M hydrochloric acid (50 mL) was added, and the mixture was stirred for 2.5 hr.
• the aqueous layer and the organic layer were separated, and the organic layer was washed with saturated brine and saturated aqueous sodium hydrogencarbonate while simultaneously adjusting to neutral.
• the organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was washed with cool hexane to give the title compound (1.89 g, yield 71%) as colorless crystals.
• the extract was washed successively with diluted hydrochloric acid, saturated aqueous sodium hydrogencarbonate and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
• the precipitated crystals were washed with petroleum ether to give the title compound (5.10 g, yield 66%) as pale-yellow crystals.
• the mother solution was concentrated under reduced pressure, and washed with petroleum ether to give second crop (1.38 g, yield 18%).
• the extract was washed successively with 1 M aqueous sodium hydroxide solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
• the extract was washed successively with 1 M aqueous sodium hydroxide solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
• the extract was washed successively with 1 M aqueous sodium hydroxide solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
• N-chlorosuccinimide (6.68 g, 50.0 mmol) by small portions under ice-cooling, and the mixture was stirred at room temperature for 13 hr, and then at 50° C. for 3 hr.
• N-Chlorosuccinimide (1.34 g, 10.0 mmol) was added to the reaction mixture, and the mixture was stirred at the same temperature for 3 hr.
• the reaction mixture was diluted with water, acidified with 1 M hydrochloric acid, and extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The precipitated crystals were recrystallized from hexane-ethyl acetate to give the title compound (0.352 g, yield 85%) as colorless crystals.
• the reaction mixture was diluted with ethyl acetate, washed successively with 1 M aqueous sodium hydroxide solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
• the reaction mixture was diluted with ethyl acetate, washed successively with aqueous sodium thiosulfate solution, 1 M aqueous sodium hydroxide solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
• the reaction mixture was diluted with water, acidified with 1 M hydrochloric acid, and extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The precipitated crystals were recrystallized from heptane-ethyl acetate to give the title compound (0.358 g, yield 76%) as colorless crystals.
• the reaction mixture was diluted with water, acidified with 1 M hydrochloric acid, and extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The precipitated crystals were recrystallized from heptane-ethyl acetate to give the title compound (0.417 g, yield 94%) as colorless crystals.
• the reaction mixture was diluted with water, and extracted with ethyl acetate.
• the extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
• the residue was purified by preparative HPLC, and the obtained crystals were recrystallized from heptane-ethyl acetate to give the title compound (0.237 g, yield 73%) as colorless crystals.
• the reaction mixture was concentrated under reduced pressure, and the residue was partitioned between diluted hydrochloric acid and ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, naturally filtered, and concentrated under reduced pressure. The residue was suspended in methanol (200 mL), concentrated sulfuric acid (14.9 mL) was added at 0° C., and the mixture was heated under reflux for 1.5 hr. The reaction mixture was concentrated under reduced pressure, ice water was added, and the mixture was extracted with ethyl acetate. The extract was washed successively with saturated aqueous sodium hydrogencarbonate and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
• the reaction mixture was diluted with water, acidified with 10% aqueous citric acid solution, and extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The precipitated crystals were recrystallized from heptane-ethyl acetate to give the title compound (0.520 g, yield 86%) as colorless crystals.
• Example 23 In the same manner as in Example 23, the title compound was obtained as a colorless oil from methyl[(3S)-6-hydroxy-2,3-dihydro-1-benzofuran-3-yl]acetate and ⁇ 3′,5′-dichloro-2′,6′-diethyl-4′-[3-(methylsulfonyl)propoxy]biphenyl-3-yl ⁇ methanol. yield 74%.
• the extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
• the obtained oil was dissolved in a mixed solvent of methanol (2 mL) and water (1 mL), and 1 M aqueous sodium hydroxide solution (0.555 mL) was added. 1 M Aqueous calcium chloride solution (0.333 mL) was added thereto.
• the precipitated solid was collected by filtration, washed with water, and dried to give the title compound (0.256 g, yield 68%) as a colorless powder.
• the total amount of the above-mentioned 1), 2) and 3) and 30 g of 4) are kneaded with water, vacuum dried and granulated.
• the granulated powder is mixed with 14 g of 4) and 1 g of 5) and tableted with a tableting machine. In this way, 1000 tablets containing 30 mg of the compound of Example 1 per tablet are obtained.
• a CHO cell line stably expressing human-derived GPR40 was used for determining the agonist activity. Unless particularly described, the CHO cell line was cultured in ⁇ -MEM medium (Invitrogen or Wako Pure Chemical Industries, Ltd.) supplemented with 10% dialyzed fetal calf serum (TRA Thermo Electron).
• the cells cultured to near confluence were rinsed with PBS (Invitrogen), detached using 0.5 mM EDTA (Wako Pure Chemical Industries, Ltd.) and recovered by centrifugation. The obtained cells were counted and diluted to 3 ⁇ 10 5 cells per 1 mL medium. The cells were dispensed to a 96-well black clear bottom plate (Coster) by 100 ⁇ L per well and cultured overnight in a CO 2 incubator. To the CHO cells prepared in this manner were added various test compounds, and variation in the intracellular calcium concentration was measured using FLIPR (Molecular Device) or Cell Lux (PerkinElmer). For measurement of variation in the intracellular calcium concentration using FLIPR or Cell Lux, the following pretreatment was performed.
• FLIPR Molecular Device
• Cell Lux PerkinElmer
• fluorescence dye Fluo3-AM (Molecular Device)
• fatty acid-free BSA was added to ⁇ -MEM medium to the final concentration of 0.1% to give an assay buffer.
• a fluorescence dye solution was prepared by dissolving 500 mM Probenecid in 1N NaOH, adding the solution to the assay buffer to the final concentration of 2.5 mM, and the resulting solution (10 mL) was added to 1 vial of component A (Molecular Device). The medium of the 96 well black clear bottom plate into which the CHO cells had been sown one day before the assay was removed.
• the cells were washed with D-PBS( ⁇ ), 50 ⁇ L of the assay buffer ( ⁇ -MEM medium added with fatty acid-free BSA, final concentration 0.1%) was further added thereto and the cells were cultured at 37° C. for 60 min in a CO 2 incubator. Then, a fluorescence dye solution was dispensed by 100 ⁇ L per well, and the cells were cultured in a CO 2 incubator for 1 hr to allow intake of the fluorescence dye.
• the assay buffer ⁇ -MEM medium added with fatty acid-free BSA, final concentration 0.16%
• test compound was diluted to a given concentration with the assay buffer, and dispensed to a polypropylene 96-well plate (sample plate) by 100 ⁇ L.
• the cell plate and the sample plate were simultaneously set in the FLIPR or Cell Lux.
• variation in the intracellular calcium concentration after addition of 50 ⁇ L of various test compounds was measured using FLIPR or Cell Lux.
• the agonist activity of each compound (1 ⁇ M) was calculated as a relative activity value when the activity of 10 ⁇ M ⁇ -linolenic acid (GPR40 agonist) was 100%. The results are shown in Table 1.
• FLIPR was employed for the assay of compounds of Examples 2, 6, 8, 10, 11 and 13, and Cell Lux was employed for the assay of compounds of Examples 19, 20, 22, 24, 26, 28, 30, 32 and 34.
• the compounds of the present invention have a superior GPR40 receptor function modulating action and are useful as insulin secretagogues or agents for the prophylaxis or treatment of diabetes and the like.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Immunology (AREA)
• Obesity (AREA)
• Physical Education & Sports Medicine (AREA)
• Endocrinology (AREA)
• Psychiatry (AREA)
• Rheumatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Pain & Pain Management (AREA)
• Urology & Nephrology (AREA)
• Oncology (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• Communicable Diseases (AREA)
• Child & Adolescent Psychology (AREA)
• Ophthalmology & Optometry (AREA)
• Emergency Medicine (AREA)
• Vascular Medicine (AREA)
• Nutrition Science (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (2)

Family

ID=38656568

Family Applications (5)

Family Applications After (4)

Country Status (37)

Cited By (2)

Families Citing this family (132)

Citations (15)

Family Cites Families (42)

• 2007
  • 2007-06-26 UA UAA200900604A patent/UA95296C2/uk unknown
  • 2007-06-26 MX MX2008016274A patent/MX2008016274A/es active IP Right Grant
  • 2007-06-26 WO PCT/JP2007/063208 patent/WO2008001931A2/en active Application Filing
  • 2007-06-26 CA CA2656003A patent/CA2656003C/en active Active
  • 2007-06-26 DK DK07767983.5T patent/DK2041123T3/da active
  • 2007-06-26 KR KR1020097001696A patent/KR101058772B1/ko not_active IP Right Cessation
  • 2007-06-26 MY MYPI20085345A patent/MY154798A/en unknown
  • 2007-06-26 GE GEAP200711077A patent/GEP20115359B/en unknown
  • 2007-06-26 SI SI200730892T patent/SI2041123T1/sl unknown
  • 2007-06-26 ES ES10172951.5T patent/ES2450081T3/es active Active
  • 2007-06-26 PT PT07767983T patent/PT2041123E/pt unknown
  • 2007-06-26 EP EP10172951.5A patent/EP2248812B1/en active Active
  • 2007-06-26 AU AU2007265966A patent/AU2007265966B2/en not_active Ceased
  • 2007-06-26 CA CA2838448A patent/CA2838448A1/en not_active Abandoned
  • 2007-06-26 NZ NZ574038A patent/NZ574038A/en not_active IP Right Cessation
  • 2007-06-26 CL CL2007001873A patent/CL2007001873A1/es unknown
  • 2007-06-26 RS RS20120169A patent/RS52307B/en unknown
  • 2007-06-26 RS RS20140115A patent/RS53230B/en unknown
  • 2007-06-26 PE PE2007000827A patent/PE20080993A1/es not_active Application Discontinuation
  • 2007-06-26 DK DK10172951.5T patent/DK2248812T5/da active
  • 2007-06-26 PL PL07767983T patent/PL2041123T3/pl unknown
  • 2007-06-26 BR BRPI0713378A patent/BRPI0713378A8/pt not_active IP Right Cessation
  • 2007-06-26 CN CN2007800320224A patent/CN101616913B/zh not_active Expired - Fee Related
  • 2007-06-26 EP EP07767983A patent/EP2041123B9/en active Active
  • 2007-06-26 AT AT07767983T patent/ATE543815T1/de active
  • 2007-06-26 RU RU2009102515/04A patent/RU2444521C2/ru active
  • 2007-06-26 JP JP2008554357A patent/JP4401428B2/ja not_active Expired - Fee Related
  • 2007-06-26 CN CN201210241482.0A patent/CN102731451B/zh not_active Expired - Fee Related
  • 2007-06-26 CN CN2012105303764A patent/CN103083307A/zh active Pending
  • 2007-06-26 PT PT101729515T patent/PT2248812E/pt unknown
  • 2007-06-26 ME MEP-2008-901A patent/ME00535B/me unknown
  • 2007-06-26 PL PL10172951T patent/PL2248812T3/pl unknown
  • 2007-06-26 US US12/308,699 patent/US7732626B2/en active Active
  • 2007-06-26 ZA ZA200900154A patent/ZA200900154B/xx unknown
  • 2007-06-26 JO JO2007260A patent/JO2969B1/en active
  • 2007-06-26 ES ES07767983T patent/ES2379661T3/es active Active
  • 2007-06-26 TW TW096122999A patent/TWI354668B/zh not_active IP Right Cessation
  • 2007-06-26 AR ARP070102823A patent/AR061644A1/es unknown
  • 2007-06-26 EP EP11194016A patent/EP2431367A3/en not_active Withdrawn
  • 2007-06-26 SI SI200731426T patent/SI2248812T1/sl unknown
  • 2007-06-26 EP EP13190005.2A patent/EP2743268A3/en not_active Withdrawn
  • 2007-06-26 CN CN2012105303389A patent/CN103070854A/zh active Pending
• 2008
  • 2008-12-15 IL IL195947A patent/IL195947A/en not_active IP Right Cessation
  • 2008-12-30 MA MA31524A patent/MA30537B1/fr unknown
• 2009
  • 2009-01-14 NO NO20090235A patent/NO20090235L/no unknown
  • 2009-01-16 CR CR10564A patent/CR10564A/es not_active IP Right Cessation
  • 2009-01-26 CO CO09006709A patent/CO6160234A2/es unknown
  • 2009-07-16 JP JP2009168271A patent/JP4917634B2/ja not_active Expired - Fee Related
  • 2009-09-30 HK HK09109075.0A patent/HK1131126A1/xx not_active IP Right Cessation
• 2010
  • 2010-03-17 US US12/659,695 patent/US8088821B2/en not_active Expired - Fee Related
• 2011
  • 2011-11-02 US US13/287,639 patent/US8492430B2/en not_active Expired - Fee Related
  • 2011-12-08 JP JP2011269300A patent/JP5409757B2/ja not_active Expired - Fee Related
• 2012
  • 2012-04-16 HR HRP20120333TT patent/HRP20120333T1/hr unknown
  • 2012-04-25 CY CY20121100396T patent/CY1112705T1/el unknown
• 2013
  • 2013-06-05 US US13/910,374 patent/US8598226B2/en not_active Expired - Fee Related
  • 2013-10-25 US US14/063,100 patent/US20140080891A1/en not_active Abandoned
• 2014
  • 2014-03-05 HR HRP20140201TT patent/HRP20140201T1/hr unknown
  • 2014-03-18 CY CY20141100213T patent/CY1114978T1/el unknown

Patent Citations (20)

Non-Patent Citations (9)

Also Published As

Similar Documents

Legal Events